ReviewExperimental hematology & oncology2025
Developments in nanotechnology approaches for the treatment of solid tumors.
Review in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- MTA-NPs induce preferential cytotoxicity, oxidative DNA damage, and mitochondrial apoptosis in human Hep-G2 hepatocellular carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Natural Photosensitizers in Cancer Therapy: A Chemo-Biodiversity Perspective on Light-Activated Natural Compounds.Chemistry & biodiversity · 2026Review
- Prospects of DNA nanotechnology in stroke repair and regeneration.Communications biology · 2026Review
- Doxorubicin-loaded chitosan/gold nanoparticles enhance anticancer effects and reduce CLMAT3 and ZNRD1-AS1 expression in colorectal cancer cells.BMC cancer · 2026Article
- Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine.Journal of nanobiotechnology · 2026Review
- Gold nanoparticles in pediatric DIPG: promise at the blood-brain barrier's price.Annals of medicine and surgery (2012) · 2026Article
- Engineered membrane-coated nanoparticles enhance ferroptosis and microtubule inhibition in prostate cancer.Journal of materials science. Materials in medicine · 2026Article
- Titanium dioxide nanoparticles in oncology: synthesis, application, and challenges.Cell biology and toxicology · 2026Review
- Marine Klebsiella sp. RR1-mediated AgNPs functionalized with matcha: synthesis, characterization, and evaluation of antibacterial, antioxidant, anti-inflammatory, and gene regulation of breast cancer potentials.Microbial cell factories · 2026Article
- Stimuli-Responsive Carbon Nanotubes for On-Demand Cancer Therapy: A Review.AAPS PharmSciTech · 2026Review
- Biomarker-Guided Drug Delivery Systems and Oral Bioavailability Enhancement.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- STING Agonist-Modified Tumor Targeting Photosensitizer Remodels Cancer-Associated Fibroblasts to Potentiate Photoimmunotherapy in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation.Experimental hematology & oncology · 2026Review
- Physicochemical design of nanobiomaterials in oncology: structure-to-function principles for sequential transport and delivery.Frontiers in oncology · 2026Review
- Combination Therapeutic Effect of Asiatic Acid & Curcumin-Loaded Liposomes Modified by Neutrophil Extracellular Traps for the Treatment of Oral Squamous Cell Carcinoma.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nanotechnology has revolutionized cancer therapy by introducing advanced drug delivery systems that enhance therapeutic efficacy while reducing adverse effects. By leveraging various nanoparticle platforms-including liposomes, polymeric nanoparticles, and inorganic nanoparticles-researchers have improved drug solubility, stability, and bioavailability. Additionally, new nanodevices are being engineered to respond to specific physiological conditions like temperature and pH variations, enabling controlled drug release and optimizing therapeutic outcomes. Beyond drug delivery, nanotechnology plays a crucial role in the theranostic field due to the functionalization of specific materials that combine tumor detection and targeted treatment features. This review analyzes the clinical impact of nanotechnology, spanning from early-phase trials to pivotal phase 3 studies that have obtained regulatory approval, while also offering a critical perspective on the preclinical domain and its translational potential for future human applications. Despite significant progress, greater attention must be placed on key challenges, such as biocompatibility barriers and the lack of regulatory standardization, to ensure the successful translation of nanomedicine into routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.